Fentanyl's Chemical Signature Is Getting Messier, Federal Scientists Find

The problem with the American fentanyl supply has never been just the fentanyl. It is what else is in the bag, and federal scientists have now documented how quickly that "else" is changing — and how little anyone knows about it in time to matter.

A study from the National Institute of Standards and Technology, published October 7 in Drug Testing and Analysis, analyzed 4,563 samples of drug residue collected nationwide between January 2024 and June 2026. Chemist Edward Sisco and his colleagues used a technique called Direct Analysis in Real Time mass spectrometry, which fingerprints a compound's chemical components in seconds rather than the tens of minutes conventional lab equipment requires. The samples came through NIST's Rapid Drug Analysis and Research program, or RaDAR, which works with public health departments, medical examiners and forensic labs to capture the chemical makeup of the illicit supply in near-real time.

What the samples showed

The additives rise and fall in cycles, each on its own schedule. Animal tranquilizers remain far more common on the East Coast than the West — and on the East Coast, xylazine, the sedative behind the wound-causing "tranq" phenomenon, is being displaced by medetomidine, a more potent relative that can trigger severe withdrawal. An industrial chemical called BTMPS, used in plastics manufacturing, has appeared in samples on both coasts since the summer of 2024; it can cause eye inflammation and burning. Western samples tend to contain fewer additives, but at higher concentrations than their eastern counterparts.

The headline finding is simpler than any of the individual chemicals: complexity itself is rising. In early 2024, a sample typically held one or two additives. Six or more is now more common. Each extra compound makes a sample harder to analyze and an overdose harder to treat, because most of the substances mixed into fentanyl are not opioids at all and therefore do not respond to naloxone alone.

Why it matters at the bedside

Most of these adulterants demand medical care that a rescue dose of naloxone does not provide — wound treatment, sedation management, withdrawal support. That is why the point of the NIST work is speed. "RaDAR enables NIST to immediately alert public health officials to the presence of new adulterants in their area, so that they can plan a more effective treatment for people who have consumed fentanyl," Sisco said.

The team is now trying to model how additives migrate between regions, with an eye toward forecasting. "Our goal is that if some new additive pops up, say in Philadelphia, we'll be able to tell public health officials when that additive is likely to show up in Delaware, Maryland or the West Coast," Sisco said. Separate surveys of ketamine additives and of a newer class of opioids called orphines — some more potent than fentanyl — are planned.

For treatment providers, the study is an argument for chemical literacy as a clinical skill, and for a harm-reduction infrastructure that can test what is actually circulating before it reaches patients. The window between a new adulterant appearing in one city and arriving in another is the window in which an early warning is worth more than a headline.